Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 2/20 | 0.47 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.47 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.47 |
| ▸ | CDK1 | P06493 | 1/20 | 0.46 |
| ▸ | ERN1 | O75460 | 5/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.40 |
| ▸ | PRKDC | P78527 | 1/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29942484 | 0.84 | CDK1 (0.65) | TRIM24TRIM33CDK1ERN1 | |
| SCHEMBL918099 | 0.84 | CDK1 (0.65) | TRIM24TRIM33CDK1ERN1 | |
| SCHEMBL21002110 | 0.83 | CDK1 (0.58) | TYRTRIM24TRIM33CDK1PIK3CD | |
| SCHEMBL21001943 | 0.83 | CA1 (0.54) | TYRTRIM24TRIM33CDK1PIK3CD | |
| SCHEMBL2735986 | 0.82 | TYR (0.48) | TYRTRIM24TRIM33CDK1ERN1 | |
| SCHEMBL12450028 | 0.80 | TYR (0.47) | TYRTRIM24TRIM33CDK1ERN1 | |
| SCHEMBL14760953 | 0.80 | XDH (0.42) | TTRPOLBMAPTTDP1 | |
| SCHEMBL29951419 | 0.80 | TYR (0.47) | TYRTRIM24TRIM33CDK1ERN1 | |
| SCHEMBL1527080 | 0.80 | TRPA1 (0.57) | TYRTRIM24TRIM33CDK1PIK3CD | |
| SCHEMBL12432290 | 0.78 | CDK1 (0.58) | CDK1MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9346768-B2 | Molecular glasses with functionalizable groups | HER MAJESTY THE QUEEN IN RIGHT OF CANADA AS REPRESENTED BY THE MINISTER OF NATIONAL DEFENSE (CA) | 2016-05-24 | — | — | US | disclosed |
| US-9328076-B2 | Molecular glasses with functionalizable groups | HER MAJESTY IN THE RIGHT OF CANADA AS REPRESENTED BY THE MINISTER OF DEFENSE (CA) | 2016-05-03 | — | — | US | disclosed |
| US-20150232433-A1 | Molecular Glasses With Functionalizable Groups | HER MAJESTY THE QUEEN IN RIGHT OF CANADA AS REPRESENTED BY THE MINISTER OF NATIONAL DEFENCE (CA) | 2015-08-20 | — | — | US | disclosed |
| EP-2562170-B1 | Process for production of 3-[5-[4-(cyclopentyloxy)-2-hydroxybenzoyl]-2-[(3-oxo-2-substituted-2,3-dihydro-1,2-benzisoxazol-6-yl)methoxy]phenyl]propionate ester and intermediate for the process | TOYAMA CHEMICAL CO LTD (JP) | 2014-10-29 | — | — | EP | disclosed |
| US-20140005370-A1 | MOLECULAR GLASSES WITH FUNCTIONALIZABLE GROUPS | HER MAJESTY THE QUEEN IN RIGHT OF CANADA AS REPRESENTED BY THE MINISTER OF NATIONAL DEFENCE (CA) | 2014-01-02 | — | — | US | disclosed |
| CN-101712697-B | Ferrocene phosphinimine ligand containing imidazole salt group, preparation thereof and application in catalyzing asymmetric allyl substitution reaction | BEIJING INST TECHNOLOGY | 2011-09-07 | — | — | CN | disclosed |
| CN-101712697-A | Ferrocene phosphinimine ligand containing imidazole salt group, preparation thereof and application in catalyzing asymmetric allyl substitution reaction | BEIJING INST TECHNOLOGY | 2010-05-26 | — | — | CN | disclosed |
| CN-1196692-C | Substituted benzopyran derivatives for the treatment of inflammation | SEARLE & CO (US) | 2005-04-13 | — | — | CN | disclosed |
| CN-1520324-A | Antiangiogenic combination thereapy for treatment of cancer | — | 2004-08-11 | — | — | CN | disclosed |
| CN-1515566-A | Substituted chromene derivative for curing inflammation | G.D. | 2004-07-28 | — | — | CN | disclosed |
| CN-1150181-C | Substituted benzopyran analogs for treatment of inflammation | GD | 2004-05-19 | — | — | CN | disclosed |
| CN-1329607-A | Substituted benzopyran analogs for the treatment of inflammation | SEARLE & CO (US) | 2002-01-02 | — | — | CN | disclosed |
| CN-1257489-A | Substituted benzopyran derivatives for the treatment of inflammation | SEARLE & CO (US) | 2000-06-21 | — | — | CN | disclosed |
| US-4317887-A | NUCLEOPHILIC-MODIFIED POLYACRYLAMIDE, POLYSTYRENE, AND DIVINYLBENZENE-STYRENE COPOLYMER; ION EXCHANGE RESINS; FIREPROOFING | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 1982-03-02 | — | — | US | disclosed |
| US-4220726-A | POLYSTYRENE OR COPOLYMER; COMPLEXING | YEDA RESEARCH & DEVELOPMENT CO. LTD. (IL) | 1980-09-02 | — | — | US | disclosed |
| US-4154674-A | SELECTIVE REMOVAL OF ANIONS OR CATIONS USING ION EXCHANGE RESINS | YEDA RESEARCH & DEVELOPMENT CO., LTD. (IL) | 1979-05-15 | — | — | US | disclosed |
| US-3974110-A | Modification of polystyrene by Friedel-Crafts reaction with substituted halo ethyl benzenes and haloethylphenols to make supports for solid phase peptide synthesis | YEDA RESEARCH & DEVELOPMENT CO. LTD. (IL) | 1976-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005370-A1 | MOLECULAR GLASSES WITH FUNCTIONALIZABLE GROUPS | GNG2, GDI1, F12 | TYR 585/4885TRIM24 3912/4885TRIM33 4556/4885 |
| US-20150232433-A1 | Molecular Glasses With Functionalizable Groups | GDI1, GNG2, F12 | TYR 589/4885TRIM24 3915/4885TRIM33 4526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.